The Effects of Glucomannan on Weight Loss
This study has been completed.
Sponsor:
New York Chiropractic College
Information provided by (Responsible Party):
Denise Holtzman MS DC, New York Chiropractic College
ClinicalTrials.gov Identifier:
NCT01709955
First received: October 16, 2012
Last updated: October 17, 2012
Last verified: October 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine if the herb, Glucomannan, is an effective non-pharmacological appetite suppressant for overweight or Class I obese patients. The study design will not include any other lifestyle changes which enhance weight loss in order to completely isolate the effects of Glucomannan as a non-pharmacological appetite suppressant.
| Condition | Intervention | Phase |
|---|---|---|
|
Obesity |
Dietary Supplement: Glucomannan Other: Placebo |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Factorial Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by New York Chiropractic College:
Primary Outcome Measures:
- Weight Loss [ Time Frame: 30 Days ] [ Designated as safety issue: No ]
| Enrollment: | 43 |
| Study Start Date: | February 2011 |
| Study Completion Date: | July 2011 |
| Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Gucomannan |
Dietary Supplement: Glucomannan
750 MG of Glucomannan in capsule form
|
| Placebo Comparator: Placebo pill |
Other: Placebo
750 mg of Cellulose powder in a capsule form
|
Eligibility| Ages Eligible for Study: | 21 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:Subjects will be recruited based upon the category of them wanting to lose 50 pounds.
Subjects must be able to swallow the capsule whole with water.
Exclusion Criteria:
- Self-reported use of prescription medication other than hormonal birth control (such as medication for diabetes, hypertension hypothyroidism, heart disease, cancer, etc.)
- Pregnancy
- Age younger than 21 or older than 60 years of age.
- Screening for hypertension during the first laboratory visit that reveals a systole greater than 120 and a diastole greater than 90.
- BMI calculations based upon height and weight measurements at the first laboratory visit that reveal a BMI less than 25 or greater than 35.
- Self-reported iron-deficiency anemia, osteoporosis, and hypoglycemia.
Contacts and Locations
No Contacts or Locations Provided
More Information
No publications provided
| Responsible Party: | Denise Holtzman MS DC, Associate professor, New York Chiropractic College |
| ClinicalTrials.gov Identifier: | NCT01709955 History of Changes |
| Other Study ID Numbers: | 10-13 |
| Study First Received: | October 16, 2012 |
| Last Updated: | October 17, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by New York Chiropractic College:
|
Obesity Overweight Glucomannan |
Additional relevant MeSH terms:
|
Obesity Overnutrition Nutrition Disorders Overweight Body Weight Signs and Symptoms |
(1-6)-alpha-glucomannan Cathartics Gastrointestinal Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 22, 2013